[1] |
HU Kangyi, CAO Linzhong, WAN Chaochao, SHANG Zhengya, YANG Xiaorui, ZHANG Yongjie.
Research progress of traditional Chinese medicine regulating mitochondrial function in the treatment of steroid-induced femoral head necrosis
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(6): 688-696.
|
[2] |
QIN Wenxiu, XU Junfeng, YANG Ting, WANG Pingfei.
Research progress on signaling pathway of tanshinoneIIA in treatment of nerve injury after ischemic stroke
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(6): 705-713.
|
[3] |
LI Yanyang, WANG Yunjiao, LV Shichao.
Effects and mechanism of traditional Chinese medicine injection in prevention and treatment of cardiotoxicity induced by antineoplastic drugs
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(5): 572-577.
|
[4] |
LI Shuang, HAN Shuzhen, DAI Yuting, XIU Minghui, DU Xianqin, HE Jianzheng, LIN Xingyao.
Progress in the prevention and treatment of traditional Chinese medicine based on the mechanism of intestinal injury of various chemotherapy
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(5): 583-593.
|
[5] |
QI Xiaofeng, LUO Yali, XIAO Mengyong, ZHOU Shiqin, ZHOU Wen, AN Fangyu, WEI Benjun, LIU Yongqi.
Research status of dialectical prevention and treatment of acute lung injury based on the theory of "Wei qi and Ying Xue"
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 429-437.
|
[6] |
CHEN Shengfu, LI Xiaolin, WANG Weigang, DU Weize, LI Maoxing.
Research progress on antipyretic effect of Chinese medicine
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(3): 334-344.
|
[7] |
LI Shanshan, GU Jingwen, ZHANG Jing, YANG Haijing, LIU Wei, YU Yiqi, ZHANG Wenhong.
Design and evaluation of clinical trials of COVID-19 vaccine and monoclonal neutralizing antibody
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(2): 190-197.
|
[8] |
TANG Jiawei, MENG Xiangzhe, SUN Xuemin, LI Yuexuan, LIU Xue, WEI Hong.
Role of vitamin D and ACE2 in COVID-19
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(11): 1292-1298.
|
[9] |
WANG Wenjuan, QI Mingrui, TIAN Limin.
Research progress on Nrf2 in diabetic cardiomyopathy and intervention of traditional Chinese medicine
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(10): 1163-1170.
|
[10] |
CHEN Ying, YUAN Yonggui.
Research progress in the treatment of depression with monome of Chinese herb, drug pairs, compound prescriptions and Chinese patent drugs
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(5): 586-593.
|
[11] |
ZHENG Lichun, WANG Xiang, WANG Wenmei.
Management strategies and suggestions on stomatological clinical trials under the influence of epidemic
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(2): 213-216.
|
[12] |
LI Xiaoning, YU Xiao, HUANG Chenlei, CAO Ruonan, LI Jie, ZHU Guoping.
Inhibitory and scavenging ability of ambroxol combined with levofloxacin on the bacterial biofilm of Klebsiella pneumoniae
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(10): 1103-1110.
|
[13] |
YU Tianyi, JIAO Guangyang, HUANG Doudou, CHEN Yong, XU Deduo, QIU Shi, CHEN Wansheng, ZHANG Feng, WANG Bolong.
Analysis of the effective components and mechanism of Yufang Fangji II for prevention of COVID-19 based on UHPLC-Q-TOF/MS and network pharmacology
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(10): 1127-1145.
|
[14] |
MU Xin, ZHAO Ying, ZHANG Lan, CUI Yimin, ZHANG Yongxiang, DU Guanhua.
Drug clinical trial of COVID-19 in China: A brief analysis
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(8): 869-877.
|
[15] |
ZHANG Lu, LIN Liangmo, LIU Keke, HUANG Yamin, HUANG Xingxing, YANG Yongyu, XIAO Jian.
Therapeutic drug monitoring and pharmacokinetics of new coronavirus pneumonia antiviral drugs
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(5): 566-575.
|